Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease
NCT ID: NCT00088673
Last Updated: 2007-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
950 participants
INTERVENTIONAL
2004-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3APS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or Female (age 50 years and older): Female must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal).
* Diagnosis of probable Alzheimer's disease based on the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA criteria).
* Severity of dementia of mild to moderate degree as assessed by the Mini Mental State Examination (MMSE) performed at the screening visit.
* Patient must be living in the community with a reliable caregiver. Participant living in an assisted living facility may be included if study medication intake is supervised and participant has a reliable caregiver.
* Potential participant must be treated with conventional Alzheimer's disease therapies and must be on stable dose for at least 4 months prior to the screening visit and during the entire study period.
* Fluency in English, French or Spanish (oral and written).
* Signed informed consent from potential participant or legal representative and caregiver.
Exclusion Criteria
* Potential participant with any other cause of dementia.
* Life expectancy less than 2 years.
* Potential participant with a clinically significant and/or uncontrolled condition or other significant medical disease.
* Use of an investigational drug within 30 days prior to the screening visit or during the entire study.
* Previous use of 3APS.
Patient recruitment is done by participating centers.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bellus Health Inc. - a GSK company
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pivotal Research Centers
Peoria, Arizona, United States
21st Century Neurology, a division of Xenoscience
Phoenix, Arizona, United States
Central Arkansas Research
Hot Springs, Arkansas, United States
Margolin Brain Institute
Fresno, California, United States
Senior Clinical Trials, Inc.
Laguna Hills, California, United States
Pacific Research Network, Inc.
San Diego, California, United States
San Francisco Clinical Research Center
San Francisco, California, United States
Radiant Research
Denver, Colorado, United States
Research Center for Clinical Studies, Inc.
Darien, Connecticut, United States
Yale University, Alzheimer's Disesase Research Unit
New Haven, Connecticut, United States
New England Research Institute
Stamford, Connecticut, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Neuropsychiatric Research Center of SouthWest Florida
Fort Myers, Florida, United States
Berma Research Group
Hialeah, Florida, United States
Tukoi Institute for Clinical Research
Miami, Florida, United States
Palm Beach Neurological Center
Palm Beach Gardens, Florida, United States
Quantum Laboratories Inc at the Memory Disorders Clinic, North Broward Medical Center
Pompano Beach, Florida, United States
Axiom Clinical Research
Tampa, Florida, United States
Byrd Alzheimer's Center and Research Institute
Tampa, Florida, United States
Stedman Clinical Trials
Tampa, Florida, United States
University of South Florida, Suncoast Gerontology Center
Tampa, Florida, United States
Premiere Research Institute Palm Beach Neurology
West Palm Beach, Florida, United States
Comprehensive Neurology Specialists, PC
Atlanta, Georgia, United States
Emory University
Atlanta, Georgia, United States
Southern Illinois University (SIU) School of Medicine, Department of Neurology
Springfield, Illinois, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
Mood & Memory Clinic - Dr Aronson
Farmington Hills, Michigan, United States
Memory Enhancement Center
Long Branch, New Jersey, United States
Neurological Associates of Albany
Albany, New York, United States
Eastside Comprehensive Medical Center
New York, New York, United States
NYU School of Medicine
New York, New York, United States
Global Research and Consulting
Olean, New York, United States
Nathan S. Kline Institute
Orangeburg, New York, United States
University of Rochester-Program in Neurobehavioral Therapeutics
Rochester, New York, United States
Richard H. Weisler, MD, PA and Associates
Raleigh, North Carolina, United States
Wake Forest University School of Medicine, Department of Psychiatry and Behavioral Medicine
Winston-Salem, North Carolina, United States
University Memory and Aging Center
Cleveland, Ohio, United States
Neurology and Neuroscience Center of Ohio
Toledo, Ohio, United States
Clinical Pharmaceuticals Trials, Inc.
Tulsa, Oklahoma, United States
CNS Research Institute
Philadelphia, Pennsylvania, United States
Farber Institute for Neurosciences
Philadelphia, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburgh ADRC
Pittsburgh, Pennsylvania, United States
CNS Research, Inc.
East Providence, Rhode Island, United States
Memory and Aging Program, Butler Hospital
Providence, Rhode Island, United States
MUSC - Alzheimer's Research and Clinical Programs
North Charleston, South Carolina, United States
Clinical Research Services at Tennessee Christian Medical Center
Madison, Tennessee, United States
University of Texas Mental Sciences Institute
Houston, Texas, United States
Air Force Villages-Freedom House Research (Study open to Air Force Village residents only)
San Antonio, Texas, United States
The Memory Clinic
Bennington, Vermont, United States
Calgary, Alberta, Canada
The Medical Arts Health Research Group, a Division of PCT Networks, Inc.
Penticton, British Columbia, Canada
St. Joseph's Hospital
Saint John, New Brunswick, Canada
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
Queen's University
Kingston, Ontario, Canada
Geriatric Clinical Trials Group, Parkwood Hospital
London, Ontario, Canada
Ottawa, Ontario, Canada
Gerontion Research
Toronto, Ontario, Canada
Sunnybrook and Women's College Health Science Centre
Toronto, Ontario, Canada
Toronto Memory Program
Toronto, Ontario, Canada
Clinique Neuro Rive-Sud
Greenfield Park, Quebec, Canada
Hôpital Maisonneuve-Rosemont, Recherche Clinique de Neurologie
Montreal, Quebec, Canada
Jewish General Hospital- Memory Clinic
Montreal, Quebec, Canada
Hôpital de l'Enfant-Jésus
Québec, Quebec, Canada
Memory & Motor Skills Disorders Clinic
Québec, Quebec, Canada
Centre de recherche Novabyss
Sherbrooke, Quebec, Canada
McGill Centre for Studies in Aging
Verdun (Montreal), Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL-758007
Identifier Type: -
Identifier Source: org_study_id